Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Document › Details

CureVac AG. (11/20/19). "Press Release: CureVac to Present at the 31st Annual Piper Jaffray Healthcare Conference". Tübingen & Boston, MA.

Region Region New York, NY
  Country United States (USA)
Organisations Organisation CureVac AG
  Group CureVac (Group)
  Organisation 2 Solebury Trout
  Group PNC Financial Services (Group)
Products Product Piper Jaffray Annual Healthcare Conference 2019 New York
  Product 2 mRNA-based drug
Index term Index term CureVac–Piper Jaffray: investor conference, 201912 supply service CureVac presents at Piper Jaffray Healthcare Conference 2019
Persons Person Menichella, Daniel L. (Dan) (Kaleido Biosciences 202010– CEO before CureVac + Bamboo Therapeutics + AGTC + Zyngenia)
  Person 2 Hoffmann, Thomas (Trout Group 201412)

CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Chief Executive Officer, Dan Menichella, will present a corporate overview at the 31st Annual Piper Jaffray Healthcare Conference in New York on December 3, 2019.

The company will also be holding one-on-one meetings. Interested parties can contact Thomas Hoffmann ( to schedule a meeting with CureVac representatives during the conference.

About CureVac AG

CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 19 years of expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. To date, CureVac has received approximately $420 million (€400 million) in equity investments, including significant investments from SAP founder Dietmar Hopp’s dievini and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others.

For more information, please visit or follow us on Twitter at @CureVacAG.


Media Contact

Thorsten Schüller, Corporate Communications
CureVac AG, Tübingen, Germany
T: +49 7071 9883-1577

Investor Relations Contact

Thomas Hoffmann
Solebury Trout
T: +1 646-378-2931

Record changed: 2019-12-23


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for CureVac (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top